MedTrace Logo

Nasal High Flow Therapy 30 Day Readmission Study

NCT02552732 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2020-08-17

Study results available
· View outcomes & findings →

Summary

The aim of this feasibility study is to provide data for a subsequent randomized controlled trial to investigate if patient outcomes will be improved after an acute COPD exacerbation using domiciliary nasal high flow therapy (NHF) compared to standard care. This feasibility study will investigate the following: process, resources, management and scientific aspects of delivering NHF as an adjunct therapy in COPD patients.

Conditions

Interventions

DEVICE

NHF with or without Oxygen

NHF using myAIRVO™ 2 will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C.

Sponsors & Collaborators

  • Medical Research Institute of New Zealand

    collaborator OTHER

  • Alana Healthcare

    collaborator UNKNOWN

  • Fisher and Paykel Healthcare

    lead INDUSTRY

Principal Investigators

  • James Fingleton, MBChB · Medical Research Institute of New Zealand

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-05-03
Completion
2017-05-03

Countries

  • United States
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02552732 on ClinicalTrials.gov